using daratumumab to treat high-risk myeloma patients
Published 2 years ago • 3.4K plays • Length 1:00:47Download video MP4
Download video MP3
Similar videos
-
6:12
ash 2018: using daratumumab early with standard myeloma combos for newly diagnosed patients
-
1:58
treatment options for patients with multiple myeloma who are resistant to daratumumab
-
15:09
subcutaneous daratumumab — dr. jonathan kaufman | mcrt webcast july 11
-
14:28
all about darzalex (daratumumab)
-
7:31
clinical trial: darzalex (daratumamab) with revlimid/velcade/dex for newly diagnosed myeloma
-
3:52
analysis of different clinical scenarios using daratumumab | rafael fonseca, md | ash 2021
-
3:57
daratumumab in the treatment of mm with high-risk cytogenetics
-
3:54
vmp daratumumab for high-risk multiple myeloma
-
1:38
daratumumab in the treatment of high-risk mgus and low-risk smoldering myeloma
-
3:15
daratumumab for the treatment of patients with multiple myeloma
-
3:19
revlimid refractory patients in daratumumab clinical trials | binod dhakal, md | ash 2022
-
11:11
rationale for selinexor treatment in daratumumab-refractory multiple myeloma patients
-
3:20
clinical trial: daratumumab with rvd, peter voorhees, md, levine cancer institute
-
59:13
furthering myeloma research in search for a cure
-
1:23
dr. landgren on using daratumumab for patients with multiple myeloma
-
2:03
total therapy 7: high response rates in high risk ndmm to daratumumab
-
1:27
risks of immunotherapy in myeloma?
-
2:21
evaluation of daratumumab for the treatment of multiple myeloma
-
3:43
what treatment is recommended for a newly diagnosed patient?